Policy Recommendations for Strengthening the Accelerated Approval Program for Oncology Drugs
Memo: Delivered to the U.S. Food and Drug Administration (FDA)
Policy
Insurance Coverage for Over-the-Counter Preventive Services Without a Prescription
Comment: Submitted to U.S. Departments of the Treasury, Labor, and Health and Human Services
Print:
On December 1, 2023, the LDI Maternal and Reproductive Health Working Group submitted a public comment in response to a Request for Information (RFI) from the U.S. Departments of the Treasury, Labor, and Health and Human Services. The RFI sought input on a proposed policy which would require insurance coverage of over-the-counter (OTC) preventive items and services without a prescription by a health care provider.
The comment highlights the obstacles that many patients, especially those from marginalized communities, face in accessing affordable birth control, and expresses the importance of and mechanisms for ensuring that OTC contraceptives are available without financial or logistical barriers.
More on Policy at LDI
Estimated Overdose Deaths Due to the One Big Beautiful Bill Act
Research Memo: Delivered to House Speaker Mike Johnson and Majority Leader John Thune
Health Impacts of SNAP Provisions in the One Big Beautiful Bill Act
Research Memo: Delivered to House Speaker Mike Johnson and Majority Leader John Thune
Projected Mortality Impacts of the Budget Reconciliation Bill
Research Memo: Response to Request for Technical Assistance
Loss of Subsidized Drug Coverage and Mortality Following Medicaid Disenrollment: Translating our Findings and Implications for Medicaid Policy
Research Memo: Supplement to Response to Request for Technical Assistance
Medicaid’s Role in Health and the Health Care Landscape: Key Takeaways from LDI Researchers
Research Memo: Delivered to Staff of U.S. Senate Committee on Finance